OR with 95% CI of developing ACPA-positive and ACPA-negative RA for overweight and obese subjects compared with normal weight subjects in total and stratified by gender
| Total | ||||
| ACPA-positive RA | ACPA-negative RA | |||
| BMI | Ca/Co* | OR (95% CI)† | Ca/Co* | OR (95% CI)† |
| Normal weight | 1231/3053 | 1.0 (reference) | 581/3053 | 1.0 (reference) |
| Overweight | 798/1978 | 1.0 (0.9–1.1) | 441/1989 | 1.1 (1.0–1.3) |
| Obesity | 313/741 | 1.1 (0.9–1.3) | 208/741 | 1.5 (1.2–1.8) |
| P for trend | 0.2 | 0.002 | ||
| Women | ||||
| ACPA-positive RA | ACPA-negative RA | |||
| BMI | Ca/Co* | Ca/Co* | Ca/Co* | OR (95% CI)‡ |
| Normal weight | 944/2426 | 1.0 (reference) | 443/2426 | 1.0 (reference) |
| Overweight | 506/1196 | 1.1 (1.0–1.3) | 261/1196 | 1.2 (1.0–1.4) |
| Obesity | 242/500 | 1.3 (1.1–1.6) | 151/500 | 1.7 (1.4–2.1) |
| P for trend | 0.009 | 0.001 | ||
| Men | ||||
| ACPA-positive RA | ACPA-negative RA | |||
| BMI | Ca/Co* | Ca/Co* | Ca/Co* | OR (95% CI)‡ |
| Normal weight | 287/627 | 1.0 (reference) | 138/627 | 1.0 (reference) |
| Overweight | 292/782 | 0.8 (0.6–1.0) | 180/782 | 1.0 (0.8–1.3) |
| Obesity | 71/241 | 0.6 (0.5–0.8) | 57/241 | 1.1 (0.8–1.5) |
| P for trend | 0.009 | 0.9 | ||
*Number of exposed cases and controls.
†Adjusted for age, gender, residential area, ancestry and study.
‡Adjusted for age, residential area, ancestry and study.
ACPA, anticitrullinated peptide antibody; BMI, body mass index; RA, rheumatoid arthritis.